The rise of multidrug-resistant (MDR) fungal pathogens, notably Candida auris, poses a critical threat to public health, particularly for immunocompromised individuals. Current antifungal treatments face challenges due to resistance against all primary medication classes, leading to high mortality rates. Traditional methods of antifungal discovery struggle due to the lack of novel targets and reduced drug efficacy. In response, innovative strategies focusing on microbial secondary metabolites are essential, as they have historically provided over 70% of antibiotics, suggesting new pathways to identify effective antifungal agents against MDR pathogens.
In recent years, the emergence of multidrug-resistant (MDR) fungal pathogens, such as Candida auris, has posed a severe threat to public health, particularly among immunocompromised individuals.
Despite centuries of progress in combating microbial infections, the rise of pathogens resistant to all primary antifungal classes highlights a critical need for innovative antifungal strategies and novel antibiotic discovery.
Antimicrobial resistance, particularly in MDR fungi, underscores the necessity of developing new antifungal agents with unique modes of action, as traditional approaches have become insufficient.
The evolution of microbial secondary metabolites has shown potential for discovering novel antifungals, as these naturally occurring compounds have historically contributed significantly to the antimicrobial arsenal.
#mdr-fungal-pathogens #candida-auris #antifungal-resistance #antibiotic-discovery #microbial-metabolites
Collection
[
|
...
]